Tirzepatide Improves Heart Failure Across the Board in Obese Patients With Preserved Ejection Fraction
Tirzepatide reduced heart failure events by up to 59% and improved exercise capacity, symptoms, quality of life, and medication burden in obese patients with HFpEF over 2 years.
Quick Facts
What This Study Found
In a double-blind randomized trial of 731 patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide (up to 15 mg weekly) produced comprehensive improvements across every clinical measure over a median of 104 weeks.
Compared to placebo, tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure events by 33–59% (hazard ratios 0.41–0.67 depending on analysis). At 52 weeks, tirzepatide improved the Kansas City Cardiomyopathy Questionnaire score by 6.9 points, increased 6-minute walk distance by 18.4 meters, improved quality of life (EQ-5D-5L), improved NYHA functional class, enhanced patient-reported well-being, and reduced heart failure medication burden. The hierarchical composite win ratio was 1.63, meaning tirzepatide patients were 63% more likely to have a better outcome than placebo patients.
Key Numbers
n=731 · HR 0.41–0.67 for CV death/worsening HF · +6.9 pts KCCQ score · +18.4 m walk distance · Win ratio 1.63 · Median 104 weeks · BMI 38.2 · Age 65.2 years
How They Did This
Double-blind, placebo-controlled randomized trial (SUMMIT trial). 731 patients with class II–IV heart failure, ejection fraction ≥50%, and BMI ≥30 were randomized to tirzepatide (titrated up to 15 mg subcutaneous weekly) or placebo added to standard heart failure therapy. Median follow-up was 104 weeks. Primary endpoints were the combined risk of cardiovascular death or worsening heart failure, and change in KCCQ Clinical Summary Score. Extended analyses included 6-minute walk distance, quality of life, NYHA class, medication burden, and a hierarchical composite.
Why This Research Matters
Heart failure with preserved ejection fraction is one of the most common and difficult-to-treat forms of heart failure, especially in people with obesity. Until recently, few therapies showed meaningful benefit. This trial demonstrates that tirzepatide doesn't just help patients lose weight — it fundamentally improves their heart failure across multiple dimensions including survival, symptoms, exercise capacity, and quality of life. Published in Circulation, this represents some of the strongest evidence yet for GLP-1 class drugs in cardiovascular disease beyond diabetes.
The Bigger Picture
This trial is part of a growing body of evidence that GLP-1 class drugs do far more than help with weight and blood sugar. The SUMMIT trial positions tirzepatide as a potential game-changer for HFpEF, a condition that affects millions and has long frustrated cardiologists. Combined with semaglutide's cardiovascular outcome trials, these results suggest that incretin-based peptides may become foundational therapies in cardiology.
What This Study Doesn't Tell Us
The study population was predominantly obese patients with HFpEF, so results may not generalize to heart failure with reduced ejection fraction or non-obese patients. The titrated dose of up to 15 mg is the maximum tirzepatide dose, which may not be tolerable for all patients. Gastrointestinal side effects typical of GLP-1 drugs were not detailed in this analysis.
Questions This Raises
- ?Are the heart failure benefits primarily driven by weight loss, or does tirzepatide have direct cardiac effects independent of weight?
- ?Would patients with heart failure and reduced ejection fraction (HFrEF) see similar benefits?
- ?How do the heart failure outcomes compare between tirzepatide and semaglutide in similar patient populations?
Trust & Context
- Key Stat:
- Up to 59% fewer heart failure events Tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure by 33–59% compared to placebo over a median of 2 years in obese HFpEF patients.
- Evidence Grade:
- This is a large, double-blind, placebo-controlled randomized trial published in Circulation with a 2-year median follow-up. It meets the highest standards for clinical evidence, with consistent benefits across multiple predefined endpoints.
- Study Age:
- Published in 2025. This is current, landmark evidence from the SUMMIT trial and represents the state of the art for tirzepatide in heart failure.
- Original Title:
- Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
- Published In:
- Circulation, 151(10), 656-668 (2025)
- Authors:
- Zile, Michael R(6), Borlaug, Barry A(17), Kramer, Christopher M(5), Baum, Seth J, Litwin, Sheldon E, Menon, Venu, Ou, Yang, Weerakkody, Govinda J, Hurt, Karla C, Kanu, Chisom, Murakami, Masahiro, Packer, Milton
- Database ID:
- RPEP-14659
Evidence Hierarchy
Frequently Asked Questions
Is tirzepatide approved for heart failure?
Not yet. Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss) is not currently FDA-approved for heart failure. However, this SUMMIT trial provides strong evidence that it could benefit obese patients with heart failure with preserved ejection fraction, and may support a future indication.
How much did patients' daily lives actually improve?
By multiple measures, patients on tirzepatide had meaningfully better lives. Their heart failure symptom scores improved by nearly 7 points (clinically significant), they walked 18 meters farther in 6 minutes, their overall quality of life improved, their NYHA functional class improved, and they needed fewer heart failure medications — all compared to placebo.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-14659APA
Zile, Michael R; Borlaug, Barry A; Kramer, Christopher M; Baum, Seth J; Litwin, Sheldon E; Menon, Venu; Ou, Yang; Weerakkody, Govinda J; Hurt, Karla C; Kanu, Chisom; Murakami, Masahiro; Packer, Milton. (2025). Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.. Circulation, 151(10), 656-668. https://doi.org/10.1161/CIRCULATIONAHA.124.072679
MLA
Zile, Michael R, et al. "Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.." Circulation, 2025. https://doi.org/10.1161/CIRCULATIONAHA.124.072679
RethinkPeptides
RethinkPeptides Research Database. "Effects of Tirzepatide on the Clinical Trajectory of Patient..." RPEP-14659. Retrieved from https://rethinkpeptides.com/research/zile-2025-effects-of-tirzepatide-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.